bevacizumab,olaparib
astrazeneca,merck,roche
['bevacizumab', 'ovarian', 'lba29', 'brca', 'olaparib']
#esmo22 lba29. overall, the addition of maintenance olaparib to bevacizumab in patients with nd hrd+ advanced ovarian cancer resulted in improved os regardless of brca1/2 mutation status. patients with hrd-neg disease did not receive benefit and have worse outcomes 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to help clinicians & educators manage the oncology information deluge